Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Early myeloablative therapy for multiple myeloma

R Alexanian¹, M A Dimopoulos, J Hester

¹University of Texas M.D. Anderson Cancer Center, Houston 77030.

|December 15, 1994

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

Seminars in hematology·2023

Same author

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.

Seminars in hematology·2023

Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023

Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Ex vivo-expanded human CD19<sup>+</sup>TIM-1<sup>+</sup> regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1/STAT3 axis.

Nature communications·2022

Early myeloablative therapy improved complete remission rates in multiple myeloma patients who previously responded. For primary resistant disease, this intensive treatment significantly prolonged survival.

Area of Science:

Hematology
Oncology
Stem Cell Transplantation

Background:

Multiple myeloma is a hematologic malignancy.
Autologous stem cell transplantation is a common treatment modality.

Purpose of the Study:

To assess the value of early myeloablative therapy supported by autologous stem cells in multiple myeloma.
To compare outcomes with non-intensive treatment for patients with socioeconomic barriers.

Main Methods:

Retrospective analysis of 72 multiple myeloma patients treated within 1 year of diagnosis.
Comparison between patients receiving early myeloablative therapy and those not receiving intensive treatment.
Stratification of patients into remission consolidation and primary refractory disease groups.

Related Experiment Videos

Main Results:

In patients previously responsive, myeloablative therapy increased complete remission from 5% to 45% (P < .01) but did not improve survival or progression-free intervals.
In primary refractory disease, myeloablative therapy controlled myeloma in 70% and prolonged median survival from 37 to 83 months (P = .03).
Delayed intensive treatment for primary resistant myeloma yielded lower response rates and shorter progression-free intervals.

Conclusions:

Early myeloablative therapy with autologous stem cells is primarily beneficial for patients with primary resistant multiple myeloma within the first year of therapy.
The treatment did not improve outcomes for patients who had previously responded to therapy.
Timely administration of intensive therapy is crucial for maximizing benefits in resistant myeloma cases.